What is the next management step for an 82‑year‑old patient on fosamax (alendronate) whose DEXA T‑score has declined from –2.6 to –2.9 despite long‑term therapy?

Management of Declining Bone Density on Long-Term Alendronate

This 82-year-old patient has experienced treatment failure on alendronate and should be reassessed for very high-risk features; if present, switch to anabolic therapy (teriparatide or romosozumab), but if only at moderate-to-high risk, consider either continuing alendronate with optimization of adherence and supplementation or transitioning to denosumab. 1

Step 1: Confirm True Treatment Failure

Before changing therapy, verify that the patient has been taking alendronate correctly, as improper administration is a common cause of apparent treatment failure 1:

• Confirm proper dosing technique: The patient must take alendronate with a full glass of water (6-8 ounces), remain upright for at least 30 minutes, and avoid food/drink during this period 2
• Verify adequate supplementation: Ensure calcium intake of 1000-1200 mg/day and vitamin D 800 IU/day, as deficiency attenuates bisphosphonate efficacy 1, 3
• Check vitamin D levels: Correct any deficiency before continuing or switching therapy, as vitamin D insufficiency increases parathyroid hormone levels and worsens bone loss 4, 2

The modest T-score decline from -2.6 to -2.9 over time on therapy, while concerning, represents a relatively small change that could reflect measurement variability rather than true progression 5.

Step 2: Risk Stratification for Treatment Decision

The American College of Physicians and American College of Rheumatology recommend categorizing patients into risk levels to guide therapy after bisphosphonate treatment 1:

Very High-Risk Features (indicating need for anabolic therapy):

• Multiple vertebral fractures 1
• Fracture occurring after ≥18 months of adequate bisphosphonate treatment 1
• Significant bone loss ≥10% per year despite bisphosphonate therapy 1
• T-score ≤ -3.0 with additional risk factors 1
• Ongoing high-dose glucocorticoid use (≥7.5 mg prednisone daily) 1

High-Risk Features (may warrant continued/intensified antiresorptive therapy):

• Age >80 years 1
• Previous hip or vertebral fractures during treatment 1
• Multiple non-spine fractures 1
• Hip BMD T-score ≤ -2.5 despite treatment 1

At 82 years old with a T-score of -2.9, this patient has at least one high-risk feature (age >80) 1.

Step 3: Treatment Algorithm Based on Risk

If Very High-Risk Features Present:

Switch to anabolic therapy first (teriparatide or romosozumab), as the American College of Rheumatology conditionally recommends anabolic agents over antiresorptive agents for patients at very high fracture risk 1. This approach is superior because:

• Anabolic agents build new bone rather than just preventing resorption 6
• They are specifically reserved for "females with primary osteoporosis at very high risk of fracture" 1
• After completing anabolic therapy, transition to an antiresorptive agent (denosumab or bisphosphonate) to preserve gains 1

If High-Risk But Not Very High-Risk (Most Likely Scenario):

You have three evidence-based options:

Option A: Continue alendronate beyond 5 years 1

• Appropriate for patients with very high ongoing fracture risk 1
• The FLEX trial showed that continuing alendronate beyond 5 years reduces clinical vertebral fractures (2.4% vs 5.3%, RR 0.45) but not non-vertebral or hip fractures 7, 1
• Increasing duration beyond 5 years probably reduces vertebral fractures but increases long-term harm risk (osteonecrosis of jaw, atypical femoral fractures) 1, 4
• Risk of atypical femoral fractures escalates significantly after 5 years, particularly beyond 8 years (1.78 to 113 per 100,000 person-years) 1

Option B: Switch to denosumab 1, 3

• Denosumab shows greater BMD increases than bisphosphonates (3.5% vs 2.6% for alendronate at the hip) 1
• Particularly appropriate if creatinine clearance <60 mL/min, as alendronate is contraindicated if CrCl <35 mL/min 1, 4
• Critical warning: Never discontinue denosumab without immediately starting bisphosphonate therapy within 6 months, as rebound vertebral fractures occur 1, 3
• Denosumab is FDA-approved for postmenopausal women with osteoporosis at high risk for fracture 1

Option C: Drug holiday (less appropriate given age 82 and declining BMD)

• Generally reserved for patients without high-risk features 1
• Not recommended for this patient given age >80 and declining T-score 1

Step 4: Practical Recommendation for This Patient

Given the patient's age of 82 years and declining T-score, I recommend continuing alendronate with optimization OR switching to denosumab, depending on the presence of additional risk factors:

Continue Optimized Alendronate If:

• No previous fractures during treatment 1
• No other very high-risk features 1
• Good renal function (CrCl >60 mL/min) 4
• Able to comply with proper administration technique 2

Ensure proper administration and supplementation:

• Verify calcium 1000-1200 mg/day and vitamin D 800 IU/day 1, 3
• Confirm proper dosing technique (upright 30 minutes, full glass water, no food) 2
• Complete any needed dental work before continuing, as osteonecrosis of jaw risk increases with cumulative exposure 1, 4

Switch to Denosumab 60 mg SC Every 6 Months If:

• Renal impairment (CrCl <60 mL/min) 1, 4
• Gastrointestinal intolerance to oral bisphosphonates 1
• Poor adherence to alendronate dosing requirements 1
• Presence of additional high-risk features beyond age 1

Step 5: Monitoring Strategy

• Do NOT perform routine BMD monitoring during continued treatment, as fracture reduction occurs even without BMD increases 1, 3
• Monitor clinically for new fractures 1
• Reassess fracture risk regularly 1
• If switching to denosumab, counsel patient that it cannot be stopped without transitioning to bisphosphonate 1, 3

Critical Pitfalls to Avoid

• Do not automatically switch therapy without first confirming proper alendronate administration and adequate calcium/vitamin D supplementation 1
• Do not ignore age >80 as an independent high-risk factor that may warrant continued treatment 1
• Do not start denosumab unless you can commit to never stopping it without transitioning to bisphosphonate within 6 months 1, 3
• Do not continue bisphosphonates beyond 8-10 years without compelling indication, as atypical femoral fracture risk escalates sharply 1, 4
• Do not delay necessary dental work; complete it before continuing or switching therapy 1, 4